United States Injectable Drug Delivery Market to hit US$ 1258.4 million by 2033 | Top Companies are Becton Dickinson & Company, Baxter International, Inc, Gerresheimer AG, Pfizer Inc, Schott AG

Global Injectable Drug Delivery Market reached US$ 744.3 million in 2024 and is expected to reach US$ 1258.4 million by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033.

DataM Intelligence has released its latest report on the "Injectable Drug Delivery Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Taisho Pharmaceutical Co., Ltd. launched the Nanozora 30mg autoinjector for subcutaneous injection, a single-use, prefilled device containing the same TNFα inhibitor as its syringe form In January 2024

United States: Recent Industry Developments
✅ October 2025: Becton Dickinson introduced advanced prefilled syringes with enhanced safety features for biologic drugs.
✅ September 2025: Pfizer expanded its portfolio of injectable therapies supported by innovative delivery devices to improve patient adherence.
✅ August 2025: FDA approved next-generation autoinjectors designed for self-administration of chronic disease medications.

Japan: Recent Industry Developments
✅ October 2025: Terumo Corporation launched smart injectable delivery systems with integrated digital tracking for dosage accuracy.
✅ September 2025: Japanese pharma companies collaborated on developing needle-free injection technologies to reduce patient discomfort.
✅ August 2025: Increased investments in biosimilar injectable formulations drove demand for improved delivery devices.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/injectable-drug-delivery-market?kb

Latest M&A

The pharma sector saw major M&A activities centered on injectable drug technologies, including Eli Lilly's acquisition of Verve Therapeutics for $1 billion, expanding gene-editing and injectable cardiovascular therapies.​

Pfizer's $10 billion acquisition of Metsera brought oral and injectable next-generation GLP-1 analogues into Pfizer's obesity and metabolic disease program.​

Several CDMO/CDMO expansions focused on sterile injectables manufacturing capacity increased in 2025 to meet rising biologic drug injectable demand

Key Player:

Becton Dickinson & Company, Baxter International, Inc, Gerresheimer AG, Pfizer Inc, Schott AG, Terumo Corporation, SHL Medical, Owen Mumford, Ypsomed, Union Medico

Key Industry Developments:

In January 2024, Credence MedSystems, a leader in pharmaceutical drug delivery innovation, completed Factory Acceptance Testing (FAT) for its Companion injection device platform on a new Clinical Assembly Line.

In June 2023, Stevanato Group, S.p.A. launched Vertiva, an On-Body Delivery System (OBDS) designed for both basal and bolus injections across various subcutaneous therapies. Featuring a single-use pod with a pre-filled 3mL ISO cartridge and a reusable controller, Vertiva offers adaptable delivery profiles for small-molecule drugs and biologics, while emphasizing sustainability and cost-effectiveness.

Forecast Projection:

The global Injectable Drug Delivery market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.

Market Intelligence Research Process:

The Injectable Drug Delivery Market Report by DataM Intelligence offers a comprehensive analysis built on a mix of primary and secondary research. It explores key factors driving the industry, including government policies, market trends, competitive landscape, technological advancements, and upcoming innovations. This in-depth study uncovers both growth opportunities and potential challenges, helping businesses navigate market fluctuations and make data-driven decisions for sustainable success.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=injectable-drug-delivery-market?kb

Key Segmentations:

By Device Type: Autoinjectors, Conventional injection devices, Pen Injectors, Wearable injectors, Others

By Application: Oncology, Autoimmune Diseases, Hormonal Disorders, Orphan Disease, Others

By Usage Pattern: Curative Care, Immunization, Other Usage Pattern

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/injectable-drug-delivery-market?kb

FAQ's

Q1: How large is the Injectable Drug Delivery Market?

Ans: The Injectable Drug Delivery Market size was valued at US$ 744.3 million in 2024 and is projected to grow to US$ 1258.4 million by 2033.

Q2: How quickly is the Injectable Drug Delivery Market expanding?

Ans: The Injectable Drug Delivery Market is forecasted to grow at a CAGR of 5.8% between 2025 and 2032, showing Annual growth momentum

Q3: Which regions are dominating the Injectable Drug Delivery Market and which are fastest-growing?

Ans: North America dominating the Injectable Drug Delivery market.

Latest News & Product Launches

FDA cleared Signos Glucose Monitoring System, an AI-enabled continuous glucose monitor aimed at weight management via personalized lifestyle guidance, reflecting innovation in wearable injectable-related devices.​

New injectable therapies targeting chronic conditions like diabetes, cancer, and autoimmune diseases continue to launch, emphasizing prefilled syringes, auto-injectors, and smart injectors.​

Injectable biologics including GLP-1 receptor agonists, monoclonal antibodies, and gene therapies remain key drug classes driving the demand for innovative delivery systems.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/injectable-drug-delivery-market?kb

FDA Approvals

Multiple new injectable biologics received FDA approval in 2025, including cancer therapies and metabolic drugs, expanding the portfolio of injectable drug delivery.​

FDA novel drug therapy approvals also included new delivery systems optimizing patient adherence and dosing precision

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Reimbursement Trends

Reimbursement frameworks for injectable biologics improved in 2025, with CMS updating outpatient hospital drug reimbursement and physician fee schedules supporting coverage of more injectable specialty drugs.​

Wellness reimbursement programs for wearable injectors and digital therapeutics integrating with injectables have expanded.​

Cost and coverage of biosimilars and generics in injectable formats are becoming more competitive due to regulatory and pricing pressures

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.